EZH2 and Endometrial Cancer Development: Insights from a Mouse Model

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Enhancer of zeste homolog 2 (EZH2) is implicated in cancer development, with documented oncogenic and tumor-suppressive functions.
• Phosphatase and tensin homolog (PTEN) is a tumor suppressor frequently altered in endometrial cancer.

Purpose of the Study:

• To investigate the impact of EZH2 deletion on endometrial cancer development driven by PTEN inactivation.
• To elucidate the specific roles of EZH2 in early carcinogenesis and later disease progression.

Main Methods:

• Generation of genetically engineered mouse models with conditional uterine deletion of Ezh2 and Pten using Pgr-Cre.
• Analysis of tumor burden, proliferation (Ki67 index), epithelial stratification, and immune cell infiltration (neutrophils).

Main Results:

• Early deletion of EZH2 in Pten-deficient mice reduced tumor burden and Ki67 index, suggesting an oncogenic role in early carcinogenesis.
• Combined Ezh2 and Pten deletion led to unfavorable disease outcomes, increased epithelial stratification, and heightened inflammatory responses.
• Disease exacerbation was linked to non-cell autonomous effects, specifically massive neutrophil accumulation, indicating an altered immune response.

Conclusions:

• EZH2 exhibits dual roles in endometrial cancer: it promotes early tumor development but contributes to disease progression through modulation of immune responses.
• The study highlights the complex interplay between EZH2, PTEN, and the tumor microenvironment in endometrial carcinogenesis.